Drugs for Gastric Cancer/Gastroesophageal Junction Cancer

Table. Drugs Prescribed for Gastric/Gastroesophageal Junction Cancer

• Drug name (generic name)
• Drug company
• Indication
• Patient support services

Drug name (generic name)
• Cyramza (ramucirumab) Injection
Drug company
• Eli Lilly
Indication
• Treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel
Patient support services
• Lilly Oncology Infused Products Co‑pay Program
  866-472-8663
  
  Lilly Cares Foundation Patient Assistance Program
  800-545-6962

Drug name (generic name)
• Enhertu (fam-trastuzumab) Injection
Drug company
• Daiichi Sankyo & AstraZeneca
Indication
• Treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a previous trastuzumab-based regimen
Patient support services
• Enhertu Patient Savings Program
  833-364-3788
  
  Enhertu Patient Assistance Program
  833-364-3788

Drug name (generic name)
• Herceptin (trastuzumab)
Drug company
• Genentech
Indications
• Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support services
• Genentech Oncology Co‑pay Assistance Program
  855-692-6729
  
  Genentech Patient Foundation
  888-941-3331

Drug name (generic name)
• Kanjinti (trastuzumab-anns) Injection
Drug company
• Amgen
Indication
• Treatment of HER2- overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support services
• Amgen FIRST STEP Co‑pay Program
  866-264-2778
  
  Amgen Safety Net Foundation
  866-264-2778

Drug name (generic name)
• Keytruda (pembrolizumab)
Drug company
• Merck
Indication
• Treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1 and is progressing during or after 2 or more lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and when appropriate, HER2-targeted therapy
  
  First-line treatment, in combination with trastuzumab, fluoropyrimidineand platinum-containing chemotherapy, of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
Patient support services
• Merck Co‑pay Assistance Program
  855-257-3932
  
  Merck Patient Assistance Program
  855-257-3932

Drug name (generic name)
• Lonsurf (trifluridine & tipiracil) Tablets
Drug company
• Taiho Oncology
Indication
• Treatment of adults with metastatic gastric or gastroesophageal junction adenocarcinoma after at least 2 lines of chemotherapy with a fluoropyrimidine, a platinum, and a taxane or irinotecan, and if appropriate, targeted therapy for HER2/neu
Patient support services
• Taiho Oncology Patient Support Co‑pay Card
  844-824-4648
  
  Taiho Oncology Patient Support Program
  844-824-4648

Drug name (generic name)
• Ogivri (trastuzumab-dkst) Injection
Drug company
• Mylan
Indication
• Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
Patient support services
• Mylan Advocate Co‑pay Assistance Program
  833-695-2623
  
  Mylan Advocate Patient Assistance
  833-695-2623

Drug name (generic name)
• Ontruzant (trastuzumab-dttb) Injection
Drug company
• Organon
Indication
• Treatment, in combination with cisplatin and capecitabine or 5-fluorouracil, of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma in patients who have not received previous treatment for metastatic disease
Patient support services
• Organon Co‑pay Assistance Program
  844-326-2986
  
  Organon Patient Assistance Program
  844-326-2986

Drug name (generic name)
• Opdivo (nivolumab)
Drug company
• Bristol Myers Squibb
Indication
• Treatment, in combination with fluoropyrimidine and platinum-containing chemotherapy, of patients with advanced or metastatic gastric cancer or gastroesophageal junction cancer
Patient support services
• BMS Oncology Co‑pay Assistance Program
  800-861-0048
  
  Bristol Myers Squibb Patient Assistance Foundation
  800-736-0003

Drug name (generic name)
• Trazimera (trastuzumab-qyyp)
Drug company
• Pfizer
Indication
• Treatment of HER2- overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with chemotherapy
Patient support services
• Pfizer Oncology Together Co‑pay Savings Program
  877-744-5675
  
  Pfizer Patient Assistance Program
  877-744-5675